Different classes of RTKs are deregulated in breast carcinoma including: the epidermal growth factor receptor family (EGFR/erbB1/HER1, Neu/erbB2/HER2, erbB3/HER-3, and erbB4/HER-4); vascular endothelial growth factor receptor (VEGFR); hepatocyte growth factor receptor (HGFR/c-Met); platelet-derived growth factor receptors (PDGFRs) and insulin-like growth factor-1 receptor (IGF-1R). Here, MET is linked to breast carcinoma.